Sleep-disordered Breathing in Postmenopausal Women

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the effectiveness of CPAP treatment to co-morbidities of sleep apnea by looking the change of the consumption of medication of the co-morbidities before and after starting the CPAP treatment.

Clinical Trial Description

Sleep-disordered breathing (SDB) is frequently linked with cardiovascular diseases including stroke and type 2 diabetes, which increase the indirect costs of sleep apnea. Also non-cardiovascular co-morbidities are possible but seldom studied. CPAP treatment reverses the increased healthcare utilization seen before the sleep apnea diagnosis. Previous studies addressing the cardiovascular co-morbidities in SDB have focused on obstructive sleep apnea and in male populations, but not on partial upper airway obstruction. Partial upper airway obstruction is common in both genders but especially in women. According to investigators' clinical experience, women with partial upper airway obstruction are especially likely to have severe symptoms from their SDB. There are scarce data on cardiovascular co-morbidities associated with partial upper airway obstruction and the female gender. To study the prevalence of co-morbidities adding to the burden of SDB (periodic obstructive breathing and partial upper airway obstruction), investigators applied a conservative but robust strategy using the governmental database of medication reimbursed by the public health insurance system. Investigators analyzed both the cardiovascular and non-cardiovascular co-morbidities in our clinical population of SDB, separately in patients with periodic obstructive breathing or with partial upper airway obstruction during sleep.Investigators found that concomitant diseases ware common in SDB. Asthma and/or COPD were surprisingly frequent, and also chronic hypertension had an increased prevalence. In addition, males had diabetes mellitus and females hypothyroidism more than general population. The results emphasize the importance of diagnosis and treatment of the co-morbidities such as asthma, COPD, hypertension, diabetes and thyroid insufficiency regardless if the patient has partial upper airway obstruction or obstructive sleep apnea. Now, investigators hypothesize that CPAP treatment reduces the consumption of medication of the co-morbidities of sleep apnea. Therefore, a retrospective analyze of 5 year before and 5 year after starting the CPAP treatment the medication consumption of the same population previously used will be conducted. To do this, the governmental database of medication reimbursed by the public health insurance system will be used. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01825291
Study type	Observational
Source	Turku University Hospital
Contact
Status	Completed
Phase
Start date	January 1999
Completion date	January 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05582070` - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction	N/A
Recruiting	`NCT03919955` - A Novel Pharmacological Therapy for Obstructive Sleep Apnea	Phase 2
Completed	`NCT03927547` - Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders	N/A
Recruiting	`NCT04007380` - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI	N/A
Completed	`NCT02188498` - Electrocardiography Data Analysis in Sleep Disorders
Completed	`NCT01503164` - Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism	N/A
Recruiting	`NCT00747890` - Surgical Treatment of Mild Obstructive Sleep Apnea	N/A
Active, not recruiting	`NCT00738179` - Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease	Phase 3
Completed	`NCT00841906` - Alice PDx User/Validation Extended Trial	N/A
Completed	`NCT00202501` - Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome	N/A
Completed	`NCT00047463` - Effects of Treating Obstructive Sleep Apnea in Epilepsy	Phase 2
Not yet recruiting	`NCT06029881` - Portable System for Non-intrusive Monitoring of Sleep
Recruiting	`NCT06093347` - Central Apnoea Monitor Study
Terminated	`NCT05445869` - Severe OSA Study (SOS)	N/A
Withdrawn	`NCT04096261` - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Recruiting	`NCT04575740` - Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea	N/A
Completed	`NCT04676191` - Validation of a Contactless Vital Signs Measurement Sensor	N/A
Recruiting	`NCT06015620` - Comorbidities Resolution After MGB Surgery and Change in Body Composition
Completed	`NCT06051097` - Metabolic Syndrome and Obstructive Sleep Apnea
Completed	`NCT05687097` - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.